Abstract
The antituberculosis drug telacebec is ineffective against Mycobacterium abscessus. A recent study suggested that TB47, a telacebec analogue, potentiated the efficacy of clofazimine against M. abscessus. Here, we report that TB47 not only is ineffective against M. abscessus in vitro but also does not potentiate the activity of clofazimine.
| Original language | English |
|---|---|
| Article number | e00964-21 |
| Journal | Antimicrobial Agents and Chemotherapy |
| Volume | 65 |
| Issue number | 12 |
| DOIs | |
| State | Published - Dec 2021 |
Bibliographical note
Publisher Copyright:Copyright © 2021 American Society for Microbiology. All Rights Reserved.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Cytochrome bcc:aa
- Nontuberculous mycobacteria
- Oxidative phosphorylation
- Q203
- Terminal oxidase
- Tuberculosis
Fingerprint
Dive into the research topics of 'The QcrB inhibitors TB47 and telacebec do not potentiate the activity of clofazimine in mycobacterium abscessus'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver